公司概述
Enveric Biosciences, Inc. (ENVB) operates within the healthcare sector as a biotechnology firm dedicated to the development of small-molecule therapeutics designed to treat anxiety, depression, and addiction disorders. The company's primary product candidate, EB-002, represents an active metabolite of psilocybin and is currently undergoing preclinical development stages. As of the latest available data, the enterprise holds a market capitalization of $3.85 million and employs a workforce of 5 individuals. These valuation figures indicate that the company is an early-stage micro-cap entity with limited financial scale, reflecting the typical characteristics of biotechnology firms in the pre-clinical phase that prioritize research and development expenditures over revenue generation.
财务健康
The company reports trailing twelve-month revenue figures as N/A, while the net income stands at $-12,131,472 and EBITDA is recorded at $-8,573,590. The substantial gap between nominal revenue and significant net losses reveals a cost structure heavily weighted towards operational expenses, including research and development costs, which are common for biotechnology companies in the pipeline-building phase. Free cash flow is reported at $-4,792,909, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating positive cash flow. This negative cash flow situation implies a reliance on existing cash balances or external financing to sustain financial flexibility until product candidates advance to later development stages. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability and that revenue, if any, has not contributed to covering direct costs or operating expenses. The company holds $4.68 million in cash and has no debt on its balance sheet. Comparing total cash against total debt shows a highly conservative balance sheet with zero leverage, as the debt-to-equity ratio is listed as N/A due to the absence of debt. The current ratio is 5.38, a figure that suggests strong short-term liquidity and an ability to cover current liabilities with current assets without difficulty. Return on equity is -304.0% and return on assets is -134.1%, metrics that reveal the company is currently destroying shareholder value on a percentage basis as it burns through capital to develop its therapeutic pipeline.
估值评估
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -1.45. The negative forward P/E implies that the market is pricing in continued losses in the near term, as the company is expected to remain unprofitable in the immediate future. The price-to-book ratio stands at 0.52, indicating that the stock is trading below its book value, which suggests the market is discounting the asset base significantly, likely due to the high risk associated with the preclinical nature of the pipeline. Alternative valuation metrics such as price-to-sales (N/A) and EV/EBITDA (0.10) further highlight the speculative nature of the valuation, where the EV/EBITDA of 0.10 reflects a valuation based on a small denominator of negative earnings. The 52-week high is $17.84 and the 52-week low is $1.75. Without a specific current price provided in the facts to calculate a precise percentage, the range demonstrates a high degree of volatility typical for small-cap biotechnology stocks. The beta value is 0.33, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it moves less dramatically than the overall market index despite its high-risk business model.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A due to the company's current financial status. In the absence of historical growth data, it is impossible to determine whether earnings are growing faster or slower than revenue, as the company is in a stage where traditional growth metrics are not yet applicable. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the payout ratio is 0.0%, it confirms that the company reinvests all available resources, including its cash reserves, into growth initiatives such as clinical trials and drug development rather than distributing income to shareholders. Consequently, the overall growth and income profile for Enveric Biosciences is characterized by a complete focus on capital reinvestment for pipeline advancement, with no current income generation or dividend distribution to investors.